Haematologica, Vol 94, Issue 9, 1326-1329 doi:10.3324/haematol.2009.007823
Copyright © 2009 by Ferrata Storti Foundation
Jingbo Zhang1,2 ,
Daoxin Ma1,2 ,
Xiaojuan Zhu1,2 ,
Xun Qu3 ,
Chunyan Ji1,2 ,
Ming Hou1,2
Our data strongly supported the hypothesis that the ITP patients were Th1 profile in accordance with previous reports,1,2 and demonstrated for the first time that up regulation of Th17 cells may be an important determinant in the evolution of ITP. In addition, the positive correlation of the percentages between Th17 and Th1 cells suggested that Th17 and Th1 cells may play a cooperative or synergetic function in the pathogenic mechanism of ITP, and the biological effects of Th17 cells by promoting a cytokine imbalance toward a Th1-type immune response may induce ITP. Also, our results suggested that Tc1 cell response was predominant in ITP, and there was a significantly positive correlation between Th1 and Tc1 in ITP. This strongly supported the hypothesis that cytotoxic T lymphocyte-mediated cytotoxicity was an alternative mechanism for platelet destruction in ITP, and demonstrated that the predominant Tc1 cells might develop and function under the influence of a particular microenvironment, probably alongside Th1 response. T-cell function derangement has been demonstrated in ITP with abnormal cytokine profiles correlated to loss of immune tolerance.9,10 Studies have suggested functional defects in CD4+CD25+ regulatory T (Treg) cells contributed to breakdown of self-tolerance in ITP.10,11 Therefore, the imbalance of Th17/Treg in ITP patients needs to be clarified. 
Jingbo Zhang and Daoxin Ma contributed equally to this work.
Copyright © 2009 by Ferrata Storti Foundation
Platelet Disorders |
Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura
1 Department of Hematology, Qilu Hospital, Shandong University, Jinan
2 The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Jinan
3 Institute of Basic Medical Sciences, Qilu Hospital, Shandong University, Jinan, China
Correspondence: Daoxin Ma, Ph. D, M.D., Associate Professor, Department of Hematology, Qilu Hospital, Shandong University, 107 WenhuaXi Road, Jinan 250012, China. Phone: international +86.531.82169887. Fax: international +86.531.86927544. E-mail:daoxinma{at}hotmail.com
Key words: Th17, Th1 Tc1, immune thrombocytopenic purpura.
T-lymphocyte abnormalities are considered important in the pathogenesis of chronic immune thrombocytopenic purpura (ITP). Both CD4+ (Th) and CD8+ (Tc) T lymphocytes can be functionally divided into type 1 (T1) and type 2 (T2) subsets based on the secretion of cytokines. Since Semple1 discovered an early Th0 and Thl cell activation in children with chronic ITP, it has become evident a higher Th1 response was closely related to the etiology and status of chronic ITP.2 Until now, there have been few studies on the Tc cell profile in ITP, and we only find one report which suggests that Tc1 cell response was predominant in active ITP patients.3 Th17 cells characterized by the production of IL-17 have recently been identified as a unique subset of Th cells.4 Considerable evidence suggests Th17 cells have been linked to the development of autoimmune diseases,5,6 so we presume that Th17 cells may be of importance in ITP. To further investigate the role of Th17, Th1 and Tc1 cells in the pathogenesis of ITP, we examined the levels and correlation of Th17, Th1 and Tc1 cells in ITP patients by intracellular cytokine analysis.
Thirty adult chronic ITP patients (16 women and 14 men; mean age 36, range 17–80 years) were enrolled by diagnostic criteria for ITP,7 and the platelet count ranged between 1 and 30x109/L, with a median count of 11x109/L. Patients with complications, i.e. viral hepatitis, diabetes, hypertension, cardiovascular diseases, pregnancy, active infection, or connective tissue diseases, were excluded. The control group consisted of 30 adult healthy volunteers matched for sex and age with the study population and platelet counts ranged from 136 to 298x109/L, with the median count of 225x109/L. Informed consent was obtained from each patient and the study was approved by the Medical Ethical Committee of Qilu Hospital of Shandong University.
Intracellular cytokines were studied by flow cytometry to reflex the cytokine-producing cells. Briefly, heparinized peripheral blood (400 µL) with an equal volume of RPMI 1640 medium was incubated for 4 h at 37°C, 5% CO2 in the presence of 25 ng/mL phorbol myristate acetate (PMA), 1 µg/mL ionomycin, and 1.7 µg/mL Monensin (Alexis Biochemicals, San Diego, CA). After incubation, the cells were stained with PE-Cy5-conjugated anti-CD3 and FITC-conjugated anti-CD8 to delimitate CD4+ T cells because CD4 was down-modulated when cells were activated by PMA.8 After the surface staining, the cells were stained with PE-conjugated anti-IL-17A for Th17 detection or PE-conjugated anti-IFN-
for Th1 detection after fixation and permeabilization. Isotype controls were given to enable correct compensation and confirm antibody specificity. All the antibodies were from eBioscience, San Diego, CA, USA. Stained cells were analyzed by flow cytometric analysis using a FACScan cytometer equipped with CellQuest software (BD Bioscience PharMingen). Th17 and Th1 cells were identified as those that were CD3+CD8–
IL-17A+ and CD3+CD8βIFN-+, and Tc1 cells were those that were CD3+CD8+IFN-+. In peripheral blood, the percentages of both Th1 and Tc1 in ITP patients increased significantly compared with controls (p<0.01 for Th1; p<0.05 for Tc1) (Figure 1C and D), and there was a significantly positive correlation between Th1 and Tc1 (r=0.58, p=0.01) in ITP patients (Figure 2A). More importantly, the percentage of Th17 in patients with ITP was markedly higher than that of normal controls (p<0.05) (Figure 1E). Also, the percentage of Th17 positively correlated with Th1(r=0.61, p=0.007) while there was no significant correlation between Th17 and Tc1(r=0.09, p=0.71) (Figure 2B and C). Among the ITP patients, there were no statistical differences of the three kinds of cells tested between primary and recurrent ITP patients (p=0.18 for Th17, p=0.36 for Th1, p=0.35 for Tc1).
 View larger version (23K): [in a new window] [Download PPT slide] |
Figure 1. Circulating percentages of Th1, Tc1 and Th17 increased in ITP patients compared with controls. (A) CD3+ T subsets were gated by flow cytometry. Plots in intern box represented CD3+ T cells. (B) Representative IFN- and IL-17 expression in CD3+CD8–T subsets (CD4+ T subsets) and CD3+CD8+ T subsets from each group was shown. The percentage of positive cells was shown in each panel. (C) The percentage of circulating Th1 was significantly higher in ITP patients (15.50±4.20%), as compared with the control group (11.6±4.23%) (p<0.01). (D) The percentage of circulating Tc1 was significantly higher in ITP patients (19.96±8.91%) than that in the control group (13.71±6.77%) (p<0.05). (E) The percentage of circulating Th17 was markedly higher in ITP patients (1.94±0.93%) than that of normal controls (1.33±0.64%) (p<0.05).
|
 View larger version (8K): [in a new window] [Download PPT slide] |
Figure 2. Correlations of Th1/Tc1, Th17/Th1 and Th17/Tc1 in ITP patients. (A) Th1 percentage positively correlated with the percentage of Tc1 (r=0.58, p=0.01). (B) Th17 percentage positively correlated with the percentage of Th1 (r=0.61, p=0.007). (C) There was no significant correlation between Th17 and Tc1 (r=0.09, p=0.71).
|
In summary, our study demonstrates Th17 may be an important determinant in the evolution of ITP along with Th1 and Tc1, suggesting that blocking the abnormality of Th17 cells is likely to be a promising therapeutic concept for ITP.
Footnotes
Jingbo Zhang and Daoxin Ma contributed equally to this work.
Funding: grants from the National Natural Science Foundation (30600680, 30471941, 30770922, 30470742, 30570779, 30600259, 30628015 and 30300312), 973 Project (2006CB503800), Key Clinical Research Project of Chinese Ministry of Health (2007–2009), Research Project of National Public Fare (200802031), the Shandong Technological Development Project (2005BS03022 and 2005GG4202018), and Taishan Scholar Fundation.
References
 TOP References |
|---|
- Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996;87:4245-54.
[Abstract/Free Full Text] - Panitsas FP, Theodoropoulou M, Kouraklis A, Karakantza M, Theodorou GL, Zoumbos NC, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 2004;103:2645-7.
[Abstract/Free Full Text] - Wang T, Zhao H, Ren H, Guo J, Xu M, Yang R, et al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 2005;90:914-23.
[Abstract/Free Full Text] - Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133-41.[CrossRef][Web of Science][Medline]
- Shahrara S, Huang Q, Mandelin AM 2nd, Pope RM. TH-17 cells in rheumatoid arthritis. Arthritis Res Ther 2008;10:R93.[CrossRef][Medline]
- Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007;8:345-50.[CrossRef][Web of Science][Medline]
- British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120:574-96.[CrossRef][Web of Science][Medline]
- Pelchen-Matthews A, Parsons IJ, Marsh M. Phorbol ester-induced downregulation of CD4 is a multistep process involving dissociation from p56lck, increased association with clathrin-coated pits, and altered endosomal sorting. J Exp Med 1993;178:1209-22.
[Abstract/Free Full Text] - Hymes KB, Karpatkin S. In vitro suppressor T lymphocyte dysfunction in autoimmune thrombocytopenic purpura associated with a complement-fixing antibody. Br J Haematol 1990;74:330-5.[Web of Science][Medline]
- Yu J, Heck S, Patel V, Levan J, Yu Y, Bussel JB, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008;112:1325-8.
[Abstract/Free Full Text] - Sakakura M, Wada H, Tawara I, Nobori T, Sugiyama T, Sagawa N, et al. Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 2007;120:187-93.[CrossRef][Web of Science][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||